SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form ARS - Annual Report to Security Holders:
SEC Accession No. 0001193125-23-138235
Filing Date
2023-05-08
Accepted
2023-05-08 16:07:03
Documents
1
Period of Report
2022-12-31
Effectiveness Date
2023-05-08

Document Format Files

Seq Description Document Type Size
1 ARS d365690dars.pdf ARS 2766412
  Complete submission text file 0001193125-23-138235.txt   3811680
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: ARS | Act: 34 | File No.: 001-39536 | Film No.: 23897750
SIC: 2836 Biological Products, (No Diagnostic Substances)